Clinical trial news round-up
- Genentech and Alkermes' investigational long-acting growth hormone Nutropin (rhGH) is as effective as conventional therapies when administered bi-monthly or monthly, according to Phase III data. This represents a significant advantage compared to current growth hormone therapies which require once-daily injections. The product comprises Genentech's recombinant human growth hormone encapsulated in Alkermes' biodegradable microspheres which release rhGH over a sustained period of time. Genentech says it will submit a New Drug Application to the US Food and Drug Administration "in the near future." Such an approval could boost market share for the company; rhGH was its best-selling drug in 1998.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze